We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Oral Cambinol Treatment Shows Potential for Blocking Development of AD

By LabMedica International staff writers
Posted on 16 May 2018
Print article
Image: A model of cambinol (small yellow structure near top center) binding to nSMAse2 enzyme (Photo courtesy of Kanagasabai Vadive, University of California, Los Angeles).
Image: A model of cambinol (small yellow structure near top center) binding to nSMAse2 enzyme (Photo courtesy of Kanagasabai Vadive, University of California, Los Angeles).
Alzheimer's disease researchers have shown that the low molecular weight drug cambinol blocks the formation of exosomes that allow the spread of insoluble, toxic tau aggregates, which are characteristic of the neurodegenerative disorder.

Tau proteins are components of the cytoskeleton of neurons, but in Alzheimer's disease, tau proteins become abnormally modified and condense into insoluble "neurofibrillary tangles" that destroy these brain cells. Furthermore, dying cells encase tau aggregates in exosome lipid vesicles, which bud off and "seed" neighboring tissues, spreading the disease.

During a screen of potential drug candidates capable of blocking the seeding of tau tangles, investigators at the University of California, Los Angeles (USA), identified the compound cambinol. Previous studies had shown that cambinol was a novel uncompetitive inhibitor of the enzyme nSMase2 (neutral sphingomyelinase 2). The enzyme nSMase2 had been found to be critically required for catalyzing the production of exosome vesicles.

The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, SIRT1/2 (silence information regulator 1 and 2). Cambinol decreased tumor necrosis factor-alpha or interleukin-1 beta-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity identified the main structural features required for nSMase2 inhibition.

In a paper published in the April 9, 2018, online edition of the journal Biochemical and Biophysical Research Communications, the investigators demonstrated that cambinol was an inhibitor of cell-to-cell tau propagation. In vitro data revealed that cambinol inhibited nSMase2 enzyme activity in dose response fashion, and suppressed exosome vesicle production while reducing tau seed propagation. In vivo testing in mice showed that cambinol could reduce the nSMase2 activity in the brain after oral administration.

"Over 200 molecules have been tested as disease-modifying Alzheimer's therapy in clinical trials, and none has yet attained the Holy Grail," said senior author Dr. Varghese John, associate professor of neurology at the University of California, Los Angeles. "Our paper describes a novel approach to slow Alzheimer's progression by showing it is possible to inhibit propagation of pathologic forms of tau."

Decreased nSMase2 catalytic activity was observed in the brains of mice given oral cambinol. "Getting molecules into the brain is a big hurdle, because most drugs do not penetrate the blood-brain barrier, said Dr. John. "Now we know we can treat animals with cambinol to determine its effect on Alzheimer's pathology and progression."

Related Links:
University of California, Los Angeles

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.